Resources
55 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 5/17/2024
The resource LEVELING UP: A Guide for Optimizing the Impact of Your RCORP Consortium to Support Rural Recovery was developed by RCORP-TA and is designed to support RCORP project directors and teams in effectively structuring, leading, and managing consortia throughout the award period and beyond.
Posted 4/26/2024
The Nitazenes Overview resource created by RCORP-TA describes what nitazenes are, how to determine if they are in your community, and how to prevent and respond to overdoses due to nitazenes. Additional resources are also provided to learn more about nitazenes.
Posted 10/23/2023 (updated 3/27/2024)
Posted 10/23/2023 (updated 3/27/2024)
The Reagan-Udall Foundation partnered with the Food and Drug Administration (FDA) for the "Mitigating Risks from Human Xylazine Exposure" virtual and in-person webinar that occurred early October 2023. This public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure and examined concrete strategies for drug development and clinical research that directly supports the mitigation and reduction of risks associated with human exposure to xylazine. The meeting materials, recordings, and slides are now available for viewing.
Posted 9/25/2023 (updated 3/27/2024)
The Substance Abuse and Mental Health Services Administration (SAMHSA) now has the "Engaging Community Coalitions to Decrease Opioid Overdose Deaths Practice Guide" available, as a product of the HEALing Communities Study (HCS).
Posted 8/25/2023 (updated 3/26/2024)
The National Institute for Health Care Management (NIHCM) provided interactive graphic reports on the trends in overdose deaths using the latest data. The interactive infographic shows the effects combined drugs, such as fentanyl and xylazine, have on overdoses.
Posted 8/18/2023 (updated 3/26/2024)
The National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network (CCTN) held an event where health care professionals and federal partners discussed xylazine-related testing, treatment, and wound care. As the White House has deemed fentanyl adulterated with xylazine an emerging threat, it is important to identify and adapt to the rapidly changing practices of patient care.
Posted 7/26/2023 (updated 3/28/2024)
This session covered how primary prevention efforts fit within each of the various stages of the Continuum of Care Model. Attendees learned how to (1) engage community stakeholders from each of the 12 sectors and (2) evidence-based practices to not only inform, but to reduce stigma and to create open dialogue as it relates to SUD.
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse and OUD and their societal consequences, (2) impacts of the opioid epidemic on rural geographic areas and populations, (3) recent emergence of synthetic opioids (e.g., fentanyl) and xylazine in the U.S. drug supply, and (4) most empirically supported treatment for patients with OUD.
Posted 7/21/2023 (updated 3/28/2024)
The Office of National Drug Control Policy (ONDCP) released a plan in response to fentanyl being adulterated or associated with xylazine, which was declared as an emerging drug threat in April 2023. Due to the effect of combining these substances, people may be less responsive to naloxone in an overdose situation. The response plan includes evidence-based prevention, treatment, and supply reduction action steps, goals, and performance measures.